Oral steroid treatment for hearing improvement in Ménière's disease and endolymphatic hydrops

Otology and Neurotology

Volumn 33, Issue 9, 2012, Pages 1685-1691

  Fisher, Laurel M ^a   Derebery, M Jennifer ^a,b   Friedman, Rick A ^a,b  

^a HOUSE RESEARCH INSTITUTE   (United States)

^b HOUSE CLINIC   (United States)

Author keywords

Endolymphatic hydrops; Hearing outcome; M ni re's disease; Steroid

Indexed keywords

ANTIINFLAMMATORY AGENT; STEROID;

AGED; ARTICLE; AUDITORY THRESHOLD; FEMALE; FOLLOW UP; HEARING IMPAIRMENT; HEMISPHERIC DOMINANCE; HUMAN; INDIVIDUALITY; MALE; MENIERE DISEASE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; PURE TONE AUDIOMETRY; RETROSPECTIVE STUDY; SPEECH AUDIOMETRY; SPEECH PERCEPTION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS; AUDIOMETRY, PURE-TONE; AUDITORY THRESHOLD; ENDOLYMPHATIC HYDROPS; FEMALE; FOLLOW-UP STUDIES; FUNCTIONAL LATERALITY; HEARING LOSS; HUMANS; INDIVIDUALITY; MALE; MENIERE DISEASE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPEECH DISCRIMINATION TESTS; SPEECH PERCEPTION; STEROIDS; TREATMENT OUTCOME;

EID: 84870339709     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0b013e31826dba83     Document Type: Article

References (47)

1. Semaan MT, Megerian CA. Contemporary perspectives on the pathophysiology of Meniere's disease: implications for treatment. Curr Opin Otolaryngol Head Neck Surg 2010;18:392-8.
2. Hallpike CS, Cairns H. Observations on the Pathology of Meniere's syndrome: (section of otology). Proc R Soc Med 1938;31:1317-36.
3. Merchant SN, Adams JC, Nadol JB Jr. Pathophysiology of Meniere's syndrome: are symptoms caused by endolymphatic hydrops? Otol Neurotol 2005;26:74-81. (Pubitemid 40130213)
4. Huppert D, Strupp M, Brandt T. Long-term course of Meniere's disease revisited. Acta Otolaryngol 2010;130:644-51.
5. Yeh TH, Herman P, Tsai MC, et al. A cationic nonselective stretchactivated channel in the Reissner's membrane of the guinea pig cochlea. Am J Physiol 1998;274(3 Pt 1):C566-76.
6. Gates G. Meniere's disease review. J Am Acad Audiol 2005;17:16-26.
7. Brookes GB. Circulating immune complexes in Meniere's disease. Arch Otolaryngol Head Neck Surg 1986;112:536-40. (Pubitemid 16043961)
8. Derebery MJ, Berliner KI. Allergy and its relation to Meniere's disease. Otolaryngol Clin North Am 2010;43:1047-58.
9. Evans KL, Baldwin DL, Bainbridge D, et al. Immune status in patients with Meniere's disease. Arch Otorhinolaryngol 1988;245:287-92.
10. Dornhoffer JL, Waner M, Arenberg IK, et al. Immunoperoxidase study of the endolymphatic sac in Meniere's disease. Laryngoscope 1993;103:1027-34. (Pubitemid 23260581)
11. Alleman AM, Dornhoffer JL, Arenberg IK, et al. Demonstration of autoantibodies to the endolymphatic sac in Meniere's disease. Laryngoscope 1997;107:211-5. (Pubitemid 27076681)
12. Derebery MJ, Rao VS, Siglock TJ, et al. Meniere's disease: an immune complex-mediated illness? Laryngoscope 1991;101:225-9.
13. Derebery MJ. The role of allergy in Meniere's disease. Otolaryngol Clin North Am 1997;30:1007-16. (Pubitemid 28028502)
14. Calabrese V, Cornelius C, Maiolino L, et al. Oxidative stress, redox homeostasis and cellular stress response in Meniere's disease: role of vitagenes. Neurochem Res 2010;35:2208-17.
15. Melki SJ, Heddon CM, Frankel JK, et al. Pharmacological protection of hearing loss in the mouse model of endolymphatic hydrops. Laryngoscope 2010;120:1637-45.
16. Coelho DH, Lalwani AK. Medical management of Meniere's disease. Laryngoscope 2008;118:1099-108.
17. Kim SH, Marcus DC. Regulation of sodium transport in the inner ear. Hear Res 2011;280:21-9.
18. Pitovski DZ, Drescher MJ, Drescher DG. Glucocorticoid receptors in themammalian inner ear: RU28362 binding sites. Hear Res 1994;77: 216-20. (Pubitemid 24201346)
19. Rarey KE, Curtis LM, ten Cate WJ. Tissue specific levels of glucocorticoid receptor within the rat inner ear. Hear Res 1993;64:205-10. (Pubitemid 23036742)
20. Terakado M, Kumagami H, Takahashi H. Distribution of glucocorticoid receptors and 11 beta-hydroxysteroid dehydrogenase isoforms in the rat inner ear. Hear Res 2011;280:148-56.
21. Trune DR, Kempton JB. Blocking the glucocorticoid receptor with RU-486 does not prevent glucocorticoid control of autoimmune mouse hearing loss. Audiol Neurootol 2009;14:423-31.
22. ten Cate WJ, Curtis LM, Rarey KE. Immunochemical detection of glucocorticoid receptors within rat cochlear and vestibular tissues. Hear Res 1992;60:199-204.
23. Pitovski DZ, Drescher MJ, Kerr TP, et al. Aldosterone mediates an increase in [3H]ouabain binding at Na+, K(+)-ATPase sites in the mammalian inner ear. Brain Res 1993;601:273-8. (Pubitemid 23047691)
24. Trune DR, Kempton JB, Gross ND. Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear. Hear Res 2006;212:22-32. (Pubitemid 43254933)
25. Arriaga MA, Goldman S. Hearing results of intratympanic steroid treatment of endolymphatic hydrops. Laryngoscope 1998;108(11 Pt 1):1682-5.
26. Doyle KJ, Bauch C, Battista R, et al. Intratympanic steroid treatment: a review. Otol Neurotol 2004;25:1034-9. (Pubitemid 39491693)
27. Hirvonen TP, Peltomaa M, Ylikoski J. Intratympanic and systemic dexamethasone for Meniere's disease. ORL J Otorhinolaryngol Relat Spec 2000;62:117-20. (Pubitemid 30248561)
28. Morales-Luckie E, Cornejo-Suarez A, Zaragoza-Contreras MA, et al. Oral administration of prednisone to control refractory vertigo in Meniere's disease: a pilot study. Otol Neurotol 2005;26:1022-6. (Pubitemid 41330722)
29. Herraiz C, Plaza G, Aparicio JM, et al. Transtympanic steroids for Meniere's disease. Otol Neurotol 2010;31:162-7.
30. Shea JJ Jr, Ge X. Dexamethasone perfusion of the labyrinth plus intravenous dexamethasone for Meniere's disease. Otolaryngol Clin North Am 1996;29:353-8. (Pubitemid 26138064)
31. Silverstein H, Isaacson E, Olds MJ, et al. Dexamethasone inner ear perfusion for the treatment of Meniere's disease: a prospective, randomized, double-blind, crossover trial. Am J Otol 1998;19:196-201. (Pubitemid 28152576)
32. Committee on Hearing and Equilibrium: Guidelines for the diagnosis and evaluation of therapy in Meniere's disease. Otolaryngol Head Neck Surg 1995;113:181-5.
33. Hu A, Parnes LS. Intratympanic steroids for inner ear disorders: a review. Audiol Neurootol 2009;14:373-82.
34. Phillips JS, Westerberg B. Intratympanic steroids for Meniere's disease or syndrome. Cochrane Database Syst Rev 2011:CD008514.
35. Chandrasekhar SS. Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otol Neurotol 2001;22:18-23. (Pubitemid 32182848)
36. Chandrasekhar SS, Rubinstein RY, Kwartler JA, et al. Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents. Otolaryngol Head Neck Surg 2000;122:521-8. (Pubitemid 30210667)
37. Plontke SK, Biegner T, Kammerer B, et al. Dexamethasone concentration gradients along scala tympani after application to the round window membrane. Otol Neurotol 2008;29:401-6. (Pubitemid 351450804)
38. Bird PA, Begg EJ, Zhang M, et al. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otol Neurotol 2007;28:1124-30. (Pubitemid 350191089)
39. Bird PA, Murray DP, Zhang M, et al. Intratympanic versus intravenous delivery of dexamethasone and dexamethasone sodium phosphate to cochlear perilymph. Otol Neurotol 2011;32:933-6.
40. Plontke SK, Mikulec AA, Salt AN. Rapid clearance of methylprednisolone after intratympanic application in humans. Comment on: Bird PA, Begg EJ, Zhang M, et al. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otol Neurotol 2007;28:1124-30.
41. Salt AN, et al. Distribution of dexamethasone and preservation of inner ear function following intratympanic delivery of a gel-based formulation. Audiol Neurootol 2011;16:323-35.
42. Salt AN, Plontke SK. Endolymphatic hydrops: pathophysiology and experimental models. Otolaryngol Clin North Am 2010;43: 971-83.
43. Megerian CA. Diameter of the cochlear nerve in endolymphatic hydrops: implications for the etiology of hearing loss in Meniere's disease. Laryngoscope 2005;115:1525-35. (Pubitemid 41330657)
44. Megerian CA, et al. A mouse model with postnatal endolymphatic hydrops and hearing loss. Hear Res 2008;237:90-105.
45. Momin SR, et al. Spiral ganglion loss outpaces inner hair cell loss in endolymphatic hydrops. Laryngoscope 2010;120:159-65.
46. Bixenstine PJ, et al. Spiral ganglion degeneration patterns in endolymphatic hydrops. Laryngoscope 2008;118:1217-23.
47. Momin SR, et al. Hearing preservation in Guinea pigs with longstanding endolymphatic hydrops. Otol Neurotol 2011;32:1583-9.